Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Jianjiao Ni"'
Publikováno v:
Radiation Oncology, Vol 19, Iss 1, Pp 1-7 (2024)
Abstract Background Small cell lung cancer (SCLC) is highly invasive with poor prognosis, and its treatment has historically been hindered due to the absence of targetable driver genomic alterations. However, the high genomic instability and replicat
Externí odkaz:
https://doaj.org/article/1593ff67ae544623ac0394fbf84586fc
Autor:
Tiantian Guo, Yue Zhou, Fei Liang, Zezhou Wang, Vincent Bourbonne, Lukas Käsmann, Nora Sundahl, Abraham Jing‐Ching Wu, Jianjiao Ni, Zhengfei Zhu
Publikováno v:
Cancer Communications, Vol 44, Iss 2, Pp 278-281 (2024)
Externí odkaz:
https://doaj.org/article/fdb09559a1de4c54b04716b5ce9cb384
Autor:
Lu Yu, Zhen Zhang, HeQing Yi, Jin Wang, Junyi Li, Xiaofeng Wang, Hui Bai, Hong Ge, Xiaoli Zheng, Jianjiao Ni, Haoran Qi, Yong Guan, Wengui Xu, Zhengfei Zhu, Ligang Xing, Andre Dekker, Leonard Wee, Alberto Traverso, Zhaoxiang Ye, Zhiyong Yuan
Publikováno v:
Radiation Oncology, Vol 19, Iss 1, Pp 1-11 (2024)
Abstract Objectives Stereotactic body radiotherapy (SBRT) is a treatment option for patients with early-stage non-small cell lung cancer (NSCLC) who are unfit for surgery. Some patients may experience distant metastasis. This study aimed to develop a
Externí odkaz:
https://doaj.org/article/b3e696f352594251a7623527ef97baa7
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-14 (2023)
Abstract Background Radiation-induced lung injury (RILI) is a prevalent complication of thoracic radiotherapy in cancer patients. A comprehensive understanding of the underlying mechanisms of RILI is essential for the development of effective prevent
Externí odkaz:
https://doaj.org/article/204d14d6cc2c4776a6d5f099c2fbbe96
Autor:
Jinmeng Zhang, Jiuang Mao, Dayu Xu, Shanshan Jiang, Tiantian Guo, Yue Zhou, Li Chu, Xi Yang, Xiao Chu, Jianjiao Ni, Zhengfei Zhu
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 6971-6979 (2023)
Abstract Introduction Considerable differences of treatment response and pattern of failure may exist between definitive chemoradiation (CRT) treated locally advanced non‐small cell lung cancer (LA‐NSCLC) patients. The clinical value of additiona
Externí odkaz:
https://doaj.org/article/cc67ce64ba544bc695d2883f1b3ab8a2
Autor:
Shanshan Jiang, Yue Zhou, Liqing Zou, Li Chu, Xiao Chu, Jianjiao Ni, Yida Li, Tiantian Guo, Xi Yang, Zhengfei Zhu
Publikováno v:
Cancer Medicine, Vol 12, Iss 4, Pp 4434-4445 (2023)
Abstract Background and Purpose Abnormal vascular network of tumor can create a hypoxic microenvironment, and reduce radiotherapy sensitivity. Normalization of tumor vasculature can be a new therapeutic strategy for sensitizing radiotherapy. This stu
Externí odkaz:
https://doaj.org/article/cea1f380dd9b45459fab252e7a438b0c
Autor:
Ya Zeng, Xi Su, Yang Zhao, Yue Zhou, Tiantian Guo, Xiao Chu, Li Chu, Xi Yang, Jianjiao Ni, Zhengfei Zhu
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Objectives: To explore the rationale and value of consolidative cranial local therapy (CLT) in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients with brain metastases (BMs). Methods: EGFR-mutant NSCLC patients
Externí odkaz:
https://doaj.org/article/7b6f209f223f4390888b45b565ecdf55
Autor:
Ya Zeng, Tiantian Guo, Yue Zhou, Yang Zhao, Li Chu, Xiao Chu, Xi Yang, Jianjiao Ni, Zhengfei Zhu
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background The clinical features, survival outcomes and patterns of treatment failure of advanced non-small cell lung cancer (NSCLC) patients harboring distinct subtypes of EGFR mutations and receiving first-line EGFR tyrosine kinases inhibi
Externí odkaz:
https://doaj.org/article/d08bf5f87f2a4718a4e3b5c148098c89
Autor:
Jianjiao Ni, Yue Zhou, Lin Wu, Xinghao Ai, Xiaorong Dong, Qian Chu, Chengbo Han, Xiaofei Wang, Zhengfei Zhu
Publikováno v:
Radiation Oncology, Vol 16, Iss 1, Pp 1-9 (2021)
Abstract Objectives The SWORD trial is the first multicenter, single arm, phase II study assessing the safety and efficacy of a PD-1 inhibitor (Sintilimab), stereotactic body radiotherapy (SBRT) and granulocyte–macrophage colony stimulating factor
Externí odkaz:
https://doaj.org/article/e4d3b7b2be994edb9656c347f8a3ac9d
Publikováno v:
Cell Death and Disease, Vol 12, Iss 7, Pp 1-10 (2021)
Abstract Bone is a frequent metastatic site of non-small cell lung cancer (NSCLC), and bone metastasis (BoM) presents significant challenges for patient survival and quality of life. Osteolytic BoM is characterised by aberrant differentiation and mal
Externí odkaz:
https://doaj.org/article/0a0d2b2950784ccdbdbacf1863d1e931